Tilray (NASDAQ:TLRY – Get Rating) had its price target decreased by Cantor Fitzgerald from $5.75 to $4.15 in a report issued on Tuesday, Benzinga reports. Cantor Fitzgerald currently has a neutral rating on the stock.
TLRY has been the topic of a number of other reports. Benchmark cut Tilray from a hold rating to a sell rating and set a $3.00 target price on the stock. in a research note on Friday, July 29th. Barclays cut their price objective on shares of Tilray from $8.50 to $4.50 and set an underweight rating on the stock in a research note on Wednesday, April 20th. Piper Sandler cut their price objective on shares of Tilray from $6.00 to $3.00 and set a neutral rating on the stock in a research note on Wednesday, June 15th. Cowen cut their price objective on shares of Tilray from $23.00 to $9.00 in a research note on Friday, July 29th. Finally, Alliance Global Partners cut their price objective on shares of Tilray from $8.00 to $5.50 and set a neutral rating on the stock in a research note on Monday, May 2nd. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus price target of $7.15.
Tilray Price Performance
Tilray stock opened at $3.90 on Tuesday. Tilray has a 12-month low of $3.00 and a 12-month high of $15.21. The stock has a market capitalization of $1.94 billion, a P/E ratio of -4.38 and a beta of 2.57. The firm’s 50-day moving average is $3.57 and its two-hundred day moving average is $5.02. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.87 and a quick ratio of 1.99.
Insider Buying and Selling at Tilray
In other Tilray news, Director Brendan Kennedy sold 350,000 shares of Tilray stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $3.09, for a total transaction of $1,081,500.00. Following the transaction, the director now owns 7,624,196 shares of the company’s stock, valued at approximately $23,558,765.64. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 3.17% of the company’s stock.
Institutional Investors Weigh In On Tilray
Several institutional investors and hedge funds have recently added to or reduced their stakes in TLRY. Confluence Wealth Services Inc. acquired a new stake in Tilray in the 4th quarter worth approximately $30,000. Dupont Capital Management Corp acquired a new stake in Tilray in the 4th quarter worth approximately $34,000. Envestnet Asset Management Inc. acquired a new stake in Tilray in the 2nd quarter worth approximately $37,000. Farmers & Merchants Trust Co of Chambersburg PA lifted its holdings in Tilray by 320.0% in the 1st quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 5,250 shares of the company’s stock worth $41,000 after purchasing an additional 4,000 shares during the last quarter. Finally, GDS Wealth Management acquired a new stake in Tilray in the 2nd quarter worth approximately $44,000. 13.84% of the stock is currently owned by institutional investors and hedge funds.
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
- Get a free copy of the StockNews.com research report on Tilray (TLRY)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.